During the last 18 months we treated 45 patients with anew combination: Ifosphamid 1g,VP-16 1oom~ ~itoxantrane 4 mg/m2,Prednisone laD mg.These cytostatic agents were given day 1-3,Prednisone was tapered gradually.
Bleomycin 15 U was given i.m. on day 15.Cycles were repeated every 3 weekm 30 patients (LB 3,1B 9,CB 6,CC 4,Cb-CC 7,Lenner~s Lymphoma 1) received this combination as salvage therapy. Two third of these patients had never achieved a stable CR with various forms of pretreatment including anthracycline containing regimens.All had advanced stage of disease. Objective response was seen in 15 patients (5 CR, io PR).In addition 7 patients had miner respons~ lasting up to 8 months. Because of these results in pretreated patients we introduced VIM~chedule in 15 untreated patients (LB 1,1B 3,CB 5,CB-CC 3, IC l,pleomorphic T-cell lymphoma 2).All but 2 patients had advanced disease. Objective response was seen in 8 of io evaluable patients.2 patients (pleomorphic T-cell lymphoma) did not respond, in 3 patients is too early to evaluate. Duration of response was rather shert. Subjective tolerance was excellent. with untreated histologically proven small cell lung =ancer were entered into a phase li study .All patients hadameasurabie tumor. The patients underwent a classical staging procedure before entering the study~ including chest X-ray, bronchoscopy, tomograms of liver und brain, bone scan, bone marrow biopsy,and blood chemistry. The courses of 50 patients sre evaluable. extensive disease 20 Treatment: lhe therapeutic regimen cons~ted of epidoxirubiclne 7Omg/m 2 ao d-a-y-y~c-~lophosph~mide lO00mg/m on day l, and vlncristine 2mg on day I. The treatment was repeated after three weeks, according to hematologic recovery, Evaluaticn of response =as made after ~ and 6 eyclesp according to crlLeria established from [Dare and NCI.
Results: As a whole, the response rate of these preliminary results was 62~, with 16~ CR (8/50) and ~6 PR (Z)/SB). Cable 2 shows the distribution of response according to possible prognostic factors. Until September 50~ h'57 patients are alive. The mean survival time of aI' patients was ~7B days, the 6 months survival cute 84~, and the ]Z months survival rate 56%. performance status and extend of disease had a significant prognostic influence on the duration of remission and survival of patients. The result of treatment also influenced significantly the survival time. i~ 250 Main side effects were alopecia and gastrointestinal disturbancies. Bone marrow depression and neurotoxielty were acceptable. Cardiotoxicit 7 was not observed.
Conclusion:
These preliminary results demonstrate the activity of EPICO in the treatment of small ceil lung cancer comparable to the combination of doxirubicine, cyctophosphamide and vincristine.
